IN183539B - - Google Patents

Info

Publication number
IN183539B
IN183539B IN26CA1998A IN183539B IN 183539 B IN183539 B IN 183539B IN 26CA1998 A IN26CA1998 A IN 26CA1998A IN 183539 B IN183539 B IN 183539B
Authority
IN
India
Application number
Other languages
English (en)
Inventor
Steven Carl Quay
Panayiotis Peri Constantinides
Karel Jay Lambert
Original Assignee
Sonus Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sonus Pharma Inc filed Critical Sonus Pharma Inc
Publication of IN183539B publication Critical patent/IN183539B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/70Nanostructure
    • Y10S977/773Nanoparticle, i.e. structure having three dimensions of 100 nm or less
    • Y10S977/775Nanosized powder or flake, e.g. nanosized catalyst
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/70Nanostructure
    • Y10S977/788Of specified organic or carbon-based composition
    • Y10S977/797Lipid particle
    • Y10S977/798Lipid particle having internalized material
    • Y10S977/799Containing biological material
    • Y10S977/801Drug
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/902Specified use of nanostructure
    • Y10S977/904Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906Drug delivery
    • Y10S977/907Liposome
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00Nanotechnology
    • Y10S977/902Specified use of nanostructure
    • Y10S977/904Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915Therapeutic or pharmaceutical composition

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IN26CA1998 1997-01-07 1998-01-06 IN183539B (instruction)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3418897P 1997-01-07 1997-01-07
US4884097P 1997-06-06 1997-06-06
US09/003,173 US6458373B1 (en) 1997-01-07 1998-01-05 Emulsion vehicle for poorly soluble drugs

Publications (1)

Publication Number Publication Date
IN183539B true IN183539B (instruction) 2000-02-05

Family

ID=27357338

Family Applications (1)

Application Number Title Priority Date Filing Date
IN26CA1998 IN183539B (instruction) 1997-01-07 1998-01-06

Country Status (15)

Country Link
US (10) US6458373B1 (instruction)
EP (1) EP0981328B1 (instruction)
JP (2) JP2001508445A (instruction)
KR (1) KR100612528B1 (instruction)
AR (1) AR011518A1 (instruction)
AT (1) ATE356611T1 (instruction)
CA (1) CA2276730C (instruction)
DE (1) DE69837328T2 (instruction)
DK (1) DK0981328T3 (instruction)
ES (1) ES2285753T3 (instruction)
IL (1) IL130737A0 (instruction)
IN (1) IN183539B (instruction)
PT (1) PT981328E (instruction)
TW (2) TW579297B (instruction)
WO (1) WO1998030205A1 (instruction)

Families Citing this family (370)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US6964946B1 (en) * 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
US8137684B2 (en) 1996-10-01 2012-03-20 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20030087954A1 (en) * 1997-01-07 2003-05-08 Sonus Pharmaceuticals, Inc. Method of treating bladder carcinoma using a Taxane/Tocopherol formulation
US20030105156A1 (en) * 1997-01-07 2003-06-05 Nagesh Palepu Method for administration of a taxane/tocopherol formulation to enhance taxane therapeutic utility
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6727280B2 (en) 1997-01-07 2004-04-27 Sonus Pharmaceuticals, Inc. Method for treating colorectal carcinoma using a taxane/tocopherol formulation
US8853260B2 (en) 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
GB9715759D0 (en) * 1997-07-26 1997-10-01 Danbiosyst Uk New emulsion formulations
IL131217A0 (en) * 1998-03-10 2001-01-28 Napro Biotherapeutics Inc Novel methods and compositions for delivery of taxanes
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
US20030059465A1 (en) * 1998-05-11 2003-03-27 Unger Evan C. Stabilized nanoparticle formulations of camptotheca derivatives
US7030155B2 (en) * 1998-06-05 2006-04-18 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6241969B1 (en) * 1998-06-26 2001-06-05 Elan Corporation Plc Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
US6174547B1 (en) * 1999-07-14 2001-01-16 Alza Corporation Dosage form comprising liquid formulation
EP1117384A1 (en) * 1998-10-01 2001-07-25 Elan Pharma International Limited Controlled release nanoparticulate compositions
US20040013613A1 (en) * 2001-05-18 2004-01-22 Jain Rajeev A Rapidly disintegrating solid oral dosage form
US8236352B2 (en) 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US6428814B1 (en) * 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US7521068B2 (en) * 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
US6071952A (en) * 1998-12-02 2000-06-06 Mylan Pharmaceuticals, Inc. Stabilized injectable pharmaceutical compositions containing taxoid anti-neoplastic agents
MXPA01005884A (es) * 1998-12-11 2002-04-24 Pharmasolutions Inc Composiciones auto-emulsionantes para medicamentos escasamente solubles en agua.
NZ512599A (en) 1998-12-30 2003-10-31 Dexcel Ltd Formulation for cyclosporin administration featuring a hydrophilic solvent and a surfactant with a HLB of less than 5
AU4053700A (en) * 1999-04-02 2000-10-23 Washington State University Research Foundation Enhanced tissue and subcellular delivery of vitamin e compounds
US20080070981A1 (en) 2000-02-23 2008-03-20 Henryk Borowy-Borowski Water-soluble compositions of bioactive lipophilic compounds
US6632443B2 (en) 2000-02-23 2003-10-14 National Research Council Of Canada Water-soluble compositions of bioactive lipophilic compounds
US6045826A (en) 1999-04-02 2000-04-04 National Research Council Of Canada Water-soluble compositions of bioactive lipophilic compounds
DE60004191T2 (de) * 1999-04-13 2004-04-22 Leo Pharma A/S Gelöste pharmazeutische zusammensetzung für die parenterale verabreichung
KR20070058028A (ko) * 1999-05-24 2007-06-07 소너스파머슈티칼즈인코포레이티드 난용성 약물용 에멀젼 부형제
KR100754352B1 (ko) * 1999-05-24 2007-08-31 소너스파머슈티칼즈인코포레이티드 난용성 약물용 에멀젼 부형제의 제조방법
EP1479382A1 (en) * 1999-06-18 2004-11-24 IVAX Research, Inc. Oral pharmaceutical compositions containing taxanes and methods for treatment employing the same
US20090104273A1 (en) * 1999-06-22 2009-04-23 Elan Pharma International Ltd. Novel nifedipine compositions
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US6982281B1 (en) 2000-11-17 2006-01-03 Lipocine Inc Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
MXPA02003203A (es) * 1999-09-27 2004-03-16 Sonus Pharma Inc Composiciones terapeuticas solubles en tocol.
US6136846A (en) 1999-10-25 2000-10-24 Supergen, Inc. Formulation for paclitaxel
US6828346B2 (en) * 1999-10-25 2004-12-07 Supergen, Inc. Methods for administration of paclitaxel
FR2803203B1 (fr) * 1999-12-31 2002-05-10 Fournier Ind & Sante Nouvelles formulations galeniques du fenofibrate
US20040009229A1 (en) * 2000-01-05 2004-01-15 Unger Evan Charles Stabilized nanoparticle formulations of camptotheca derivatives
AU2001225432A1 (en) * 2000-01-20 2001-07-31 Supratek Pharma, Inc. Novel podophyllotoxin compositions
US6589968B2 (en) 2001-02-13 2003-07-08 Kosan Biosciences, Inc. Epothilone compounds and methods for making and using the same
US8618085B2 (en) * 2000-04-28 2013-12-31 Koasn Biosciences Incorporated Therapeutic formulations of desoxyepothilones
US20040156872A1 (en) * 2000-05-18 2004-08-12 Elan Pharma International Ltd. Novel nimesulide compositions
GB0016876D0 (en) * 2000-07-11 2000-08-30 Astrazeneca Ab Novel formulation
ES2238050T3 (es) * 2000-07-24 2005-08-16 PHARMACIA & UPJOHN COMPANY LLC Sistemas emulsionantes de liberacion de farmacos para farmacos lipofilos extremadamente insolubles en agua.
US7198795B2 (en) 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
AU2001293177A1 (en) * 2000-09-27 2002-04-08 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
AUPR549901A0 (en) 2001-06-06 2001-07-12 Vital Health Sciences Pty Ltd Topical formulation containing tocopheryl phosphates
BRPI0115953B8 (pt) * 2000-11-14 2021-05-25 Vital Health Sciences Pty Ltd complexos de derivados de fosfato
MXPA03004546A (es) * 2000-11-22 2003-09-10 Rxkinetix Inc Tratamiento de mucositis.
AU2002239282A1 (en) * 2000-11-28 2002-06-11 Transform Pharmaceuticals, Inc. Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
AU1987802A (en) * 2000-11-29 2002-06-11 Lyotropic Therapeutics Llc Solvent systems for pharmaceutical agents
ES2316489T3 (es) * 2000-12-05 2009-04-16 Childrens Hospital Los Angeles Composiciones farmaceuticas de fenretinida que tienen biodisponibilidad aumentada y metodos de uso de las mismas.
IN188917B (instruction) * 2000-12-07 2002-11-23 Bharat Surums & Vaccines Ltd
US20040022862A1 (en) * 2000-12-22 2004-02-05 Kipp James E. Method for preparing small particles
US6977085B2 (en) * 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US20030072807A1 (en) * 2000-12-22 2003-04-17 Wong Joseph Chung-Tak Solid particulate antifungal compositions for pharmaceutical use
US20050048126A1 (en) 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US8067032B2 (en) * 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US7193084B2 (en) * 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US20030096013A1 (en) * 2000-12-22 2003-05-22 Jane Werling Preparation of submicron sized particles with polymorph control
US9700866B2 (en) 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
US6893859B2 (en) 2001-02-13 2005-05-17 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
AU2002317053B2 (en) 2001-07-27 2004-08-05 Vital Health Sciences Pty Ltd Dermal therapy using phosphate derivatives of electron transfer agents
AUPR684801A0 (en) * 2001-08-06 2001-08-30 Vital Health Sciences Pty Ltd Supplement therapy
US20030099674A1 (en) * 2001-08-11 2003-05-29 Chen Andrew X. Lyophilized injectable formulations containing paclitaxel or other taxoid drugs
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
WO2003026611A2 (en) 2001-09-26 2003-04-03 Baxter International Inc. Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
US6858227B1 (en) 2001-11-21 2005-02-22 Sonus Pharmaceuticals, Inc. Vitamin E conjugates
US20040092428A1 (en) * 2001-11-27 2004-05-13 Hongming Chen Oral pharmaceuticals formulation comprising paclitaxel, derivatives and methods of administration thereof
CN100391464C (zh) * 2001-12-03 2008-06-04 诺瓦西股份有限公司 含活性维生素d化合物的药物组合物
AU2002353118A1 (en) * 2001-12-11 2003-07-24 Dor Biopharma, Inc. Lipid particles and suspensions and uses thereof
CN1604772A (zh) * 2001-12-13 2005-04-06 生命健康科学有限公司 化合物的透皮转运
DK1471887T3 (da) 2002-02-04 2010-06-07 Elan Pharma Int Ltd Nanopartikelkompositioner der har lysozym som overfladestabiliseringsmiddel
US6683194B2 (en) * 2002-02-05 2004-01-27 Sonus Pharmaceuticals, Inc. Tocopherol derivatives
US7635463B2 (en) * 2002-02-27 2009-12-22 Pharmain Corporation Compositions for delivery of therapeutics and other materials
JP2005524657A (ja) * 2002-02-27 2005-08-18 ファーメイン, エルティーディー. 治療剤及び他の物質を送達するための組成物、及び、前記組成物を作製し使用する方法
EP1340497A1 (en) * 2002-03-01 2003-09-03 Novagali Sas Self emulsifying drug delivery systems for poorly soluble drugs
WO2003074027A2 (en) * 2002-03-01 2003-09-12 Novagali Pharma Sa Self emulsifying drug delivery systems for poorly soluble drugs
US6825229B2 (en) 2002-03-07 2004-11-30 Blanchette Rockefeller Neurosciences Institute Methods for Alzheimer's Disease treatment and cognitive enhancement
US20080004332A1 (en) * 2002-03-07 2008-01-03 Alkon Daniel L Methods for alzheimer's disease treatment and cognitive enhancement
US20050065205A1 (en) * 2002-03-07 2005-03-24 Daniel Alkon Methods for Alzheimer's disease treatment and cognitive enhance
AU2003230691A1 (en) * 2002-03-20 2003-10-08 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
US7101576B2 (en) 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
US20040105889A1 (en) * 2002-12-03 2004-06-03 Elan Pharma International Limited Low viscosity liquid dosage forms
KR20100110378A (ko) 2002-05-24 2010-10-12 안지오테크 인터내셔날 아게 의료용 임플란트를 피복하기 위한 조성물 및 방법
FR2840614B1 (fr) * 2002-06-07 2004-08-27 Flamel Tech Sa Polyaminoacides fonctionnalises par de l'alpha-tocopherol et leurs applications notamment therapeutiques
CA2492488A1 (en) * 2002-07-16 2004-01-22 Elan Pharma International, Ltd. Liquid dosage compositions of stable nanoparticulate active agents
CA2493878C (en) 2002-07-30 2013-07-23 Wyeth Parenteral formulations containing a rapamycin hydroxyester
AU2002950713A0 (en) 2002-08-09 2002-09-12 Vital Health Sciences Pty Ltd Carrier
US7718189B2 (en) 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
DE60330703D1 (de) 2002-11-07 2010-02-04 Kosan Biosciences Inc Trans-9,10-dehydroepothilon c und d, analoga davon und verfahren zu deren herstellung
KR100507771B1 (ko) * 2002-11-08 2005-08-17 한미약품 주식회사 난용성 감기약 활성 성분의 경구투여용 조성물 및 그의제조 방법
US20050026877A1 (en) * 2002-12-03 2005-02-03 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
EP1585548B1 (en) 2002-12-09 2018-06-27 Abraxis BioScience, LLC Compositions and methods of delivery of pharmacological agents
US20040115287A1 (en) * 2002-12-17 2004-06-17 Lipocine, Inc. Hydrophobic active agent compositions and methods
KR100502821B1 (ko) 2002-12-26 2005-07-22 이호영 구리산화물 또는 구리 나노와이어로 이루어진 전자방출팁의 저온 형성 방법 및 이 방법에 의해 제조된 전자방출팁을 포함하는 디스플레이 장치 또는 광원
ES2376875T3 (es) * 2003-02-14 2012-03-20 Children's Hospital & Research Center At Oakland Vehículo de administración de fármacos lipofílicos y métodos de utilización del mismo
US20050196370A1 (en) * 2003-03-18 2005-09-08 Zhi-Jian Yu Stable ophthalmic oil-in-water emulsions with sodium hyaluronate for alleviating dry eye
US20040185068A1 (en) * 2003-03-18 2004-09-23 Zhi-Jian Yu Self-emulsifying compositions, methods of use and preparation
US20060251685A1 (en) * 2003-03-18 2006-11-09 Zhi-Jian Yu Stable ophthalmic oil-in-water emulsions with Omega-3 fatty acids for alleviating dry eye
WO2004091506A2 (en) * 2003-04-10 2004-10-28 Ivax Research, Inc. Taxane-based compositions and methods of use
US7485671B2 (en) 2003-05-16 2009-02-03 Velocys, Inc. Process for forming an emulsion using microchannel process technology
US7307104B2 (en) 2003-05-16 2007-12-11 Velocys, Inc. Process for forming an emulsion using microchannel process technology
US7691838B2 (en) 2003-05-30 2010-04-06 Kosan Biosciences Incorporated Method for treating diseases using HSP90-inhibiting agents in combination with antimitotics
US20050020546A1 (en) * 2003-06-11 2005-01-27 Novacea, Inc. Pharmaceutical compositions comprising active vitamin D compounds
US20060189586A1 (en) * 2003-06-11 2006-08-24 Cleland Jeffrey L Pharmaceutical compositions comprising active vitamin D compounds
EP1498120A1 (en) * 2003-07-18 2005-01-19 Aventis Pharma S.A. Semi-solid formulations for the oral administration of taxoids
US20060292186A1 (en) * 2003-08-29 2006-12-28 Novagali Pharma Sa Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs
EP1510206A1 (en) * 2003-08-29 2005-03-02 Novagali Pharma SA Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs
US20050107465A1 (en) * 2003-10-01 2005-05-19 Papas Andreas M. Composition for treating inflammatory bowel disease
US20050074444A1 (en) * 2003-10-01 2005-04-07 Papas Andreas M. Coenzyme Q10 treatment for cystic fibrosis
CN100471886C (zh) * 2003-10-10 2009-03-25 株式会社三养社 两亲嵌段共聚物以及包含它的用于给药的聚合组合物
JP4235226B2 (ja) * 2003-10-10 2009-03-11 サムヤン コーポレイション 両親媒性ブロック共重合体及びそれを含む薬剤送達用高分子組成物
US7311901B2 (en) * 2003-10-10 2007-12-25 Samyang Corporation Amphiphilic block copolymer and polymeric composition comprising the same for drug delivery
DE10347994A1 (de) * 2003-10-15 2005-06-16 Pari GmbH Spezialisten für effektive Inhalation Wässrige Aerosol-Zubereitung
AU2004285037B2 (en) * 2003-10-29 2010-07-22 Sonus Pharmaceuticals, Inc. Tocopherol-modified therapeutic drug compounds
US20080045559A1 (en) * 2003-10-29 2008-02-21 Sonus Pharmaceuticals, Inc. Tocopherol-modified therapeutic drug compounds
US20050096365A1 (en) * 2003-11-03 2005-05-05 David Fikstad Pharmaceutical compositions with synchronized solubilizer release
US20060003002A1 (en) * 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
TWI350183B (en) * 2003-12-31 2011-10-11 Ind Tech Res Inst A liposome and a preparation method
US20050158329A1 (en) * 2004-01-21 2005-07-21 Ghosh Swapan K. Novel phytol derived immunoadjuvants and their use in vaccine formulations
EP1720551B9 (en) * 2004-03-03 2011-09-21 Vital Health Sciences Pty Ltd. Alkaloid formulations
US20050209315A1 (en) * 2004-03-20 2005-09-22 Papas Andreas M Bioavailable nutritional supplement and method of treatment of malabsorption
US8003122B2 (en) * 2004-03-31 2011-08-23 Cordis Corporation Device for local and/or regional delivery employing liquid formulations of therapeutic agents
US7989490B2 (en) 2004-06-02 2011-08-02 Cordis Corporation Injectable formulations of taxanes for cad treatment
US20050220866A1 (en) * 2004-04-02 2005-10-06 Dr. Reddy's Laboratories Limited Novel capsule formulations of etoposide for oral use
US20050226932A1 (en) * 2004-04-09 2005-10-13 Samyang Corporation Pharmaceutical formulations for itraconazole
KR20050099311A (ko) * 2004-04-09 2005-10-13 에이엔에이치 케어연구소(주) 주사제용 항암제 조성물
WO2005112977A2 (en) * 2004-04-23 2005-12-01 Pharmain, Ltd. Compositions for treatment with glucagon-like peptide, and methods of making and using the same
TW200538181A (en) 2004-05-18 2005-12-01 Brni Neurosciences Inst Treatment of depressive disorders
KR100582604B1 (ko) 2004-06-16 2006-05-23 보람제약주식회사 항산화제를 포함한 이부프로펜 및 덱시부프로펜의마이크로 에멀젼과 이를 이용한 투명 액제 및 투명연질캡슐 제제
KR20070059072A (ko) * 2004-07-28 2007-06-11 에스디 파마슈티칼스 인코포레이티드 알파 토코페릴 석시네이트, 이의 동족체 및 이의 염의안정한 주사용 조성물
BRPI0513673B8 (pt) * 2004-08-03 2021-07-27 Vital Health Sciences Pty Ltd método para produzir um medicamento para aumentar a eficácia e o transporte dos compostos biologicamente ativos enteralmente administrados, e composição farmacêutica
KR100623013B1 (ko) * 2004-09-04 2006-09-19 김영대 나노에멀션, 그의 용도 및 제조방법
US8557861B2 (en) * 2004-09-28 2013-10-15 Mast Therapeutics, Inc. Low oil emulsion compositions for delivering taxoids and other insoluble drugs
US20060165769A1 (en) * 2004-09-30 2006-07-27 Hyatt John A Pharmaceutical formulations containing vitamin E TPGS molecules that solubilize lipophilic drugs without significant efflux inhibition, and use of such formulations
CA2582378C (en) 2004-10-01 2013-12-10 Velocys, Inc. Multiphase mixing process using microchannel process technology
US20080038316A1 (en) * 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
US20060088558A1 (en) * 2004-10-26 2006-04-27 Robert Jandzinski Vitamin E TPGS fluid concentrate comprising a low percentage of water
WO2006057895A2 (en) * 2004-11-17 2006-06-01 Velocys Inc. Process for making or treating an emulsion using microchannel technology
GT200500310A (es) 2004-11-19 2006-06-19 Compuestos organicos
US20060147518A1 (en) * 2004-12-30 2006-07-06 Pierre Fabre Medicament Stable solid dispersion of a derivative of vinca alkaloid and process for manufacturing it
JP4877899B2 (ja) * 2005-01-25 2012-02-15 学校法人近畿大学 薬物徐放出性球状微粒子及びその製造方法
US20090239827A1 (en) * 2005-03-03 2009-09-24 Esra Ogru Compounds having lipid lowering properties
US20060222716A1 (en) * 2005-04-01 2006-10-05 Joseph Schwarz Colloidal solid lipid vehicle for pharmaceutical use
EP1871343A2 (en) * 2005-04-12 2008-01-02 Wisconsin Alumni Research Foundation Micelle composition of polymer and passenger drug
US20060240051A1 (en) * 2005-04-26 2006-10-26 Singleton Andy H Eutectic blends containing a water soluble vitamin derivative
US7691392B2 (en) 2005-04-29 2010-04-06 Kosan Biosciences Incorporated Method of treating multiple myeloma using 17-AAG or 17-AG or a prodrug of either
WO2006134864A1 (ja) * 2005-06-13 2006-12-21 Dainippon Sumitomo Pharma Co., Ltd. 可溶化型製剤
KR20080019228A (ko) * 2005-06-17 2008-03-03 바이탈 헬스 사이언시즈 피티와이 리미티드 하나 이상의 디 및/또는 모노-(전자전달제) 인산염 유도체또는 그의 착염을 함유하는 담체
KR20130122630A (ko) 2005-07-29 2013-11-07 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 단독의 또는 pkc 억제제와 배합된 pkc 활성화제의 장기 기억 향상을 위한 용도
AU2006280511A1 (en) * 2005-08-12 2007-02-22 Astrazeneca Ab Process
ATE538139T1 (de) * 2005-08-30 2012-01-15 Lanxess Deutschland Gmbh Verwendung von katalysatoren für den metatheseabbau von nitrilkautschuk
US20090306198A1 (en) * 2005-09-16 2009-12-10 Robert Nicolosi Anti-Oxidant Synergy Formulation Nanoemulsions to Treat Caner
JP2009513642A (ja) * 2005-10-25 2009-04-02 アボット・ラボラトリーズ 低水溶解度の薬剤を含む製剤およびそれの使用方法
WO2007056424A2 (en) * 2005-11-07 2007-05-18 Penwest Pharmaceuticals, Co. Controlled-release emulsion compositions
US8022054B2 (en) 2005-11-28 2011-09-20 Marinus Pharmaceuticals Liquid ganaxolone formulations and methods for the making and use thereof
EP1965787B1 (en) * 2005-11-30 2013-04-10 Endo Pharmaceuticals Inc. Treatment of xerostomia with a sulfur-containing antioxidant
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
CA2896083A1 (en) 2005-12-08 2007-06-14 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof
JP2009520040A (ja) 2005-12-19 2009-05-21 ファーマイン コーポレーション 治療薬の送達のための疎水性コアの担体組成物、及び同担体組成物の作製法及び使用法
CN101011355B (zh) 2006-02-01 2013-01-02 陈献 经维生素e琥珀酸酯稳定的医药组合物、其制备及用途
TWI376239B (en) * 2006-02-01 2012-11-11 Andrew Xian Chen Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
PT1993515E (pt) * 2006-03-10 2009-11-05 Laboswiss Ag Um método para solubilização, dispersão e estabilização de compostos, produtos obtidos por esse método, assim como a sua utilização
CA2649388A1 (en) 2006-04-20 2007-11-01 Velocys, Inc. Process for treating and/or forming a non-newtonian fluid using microchannel process technology
US8112292B2 (en) 2006-04-21 2012-02-07 Medtronic Navigation, Inc. Method and apparatus for optimizing a therapy
KR100917809B1 (ko) 2006-05-22 2009-09-18 에스케이케미칼주식회사 우수한 저장안정성을 갖는 도세탁셀 함유 주사제 조성물
EP2056818B1 (en) 2006-08-11 2011-05-25 The Johns Hopkins University Compositions and methods for neuroprotection
CA2847852A1 (en) 2006-09-22 2008-04-03 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
US8660635B2 (en) 2006-09-29 2014-02-25 Medtronic, Inc. Method and apparatus for optimizing a computer assisted surgical procedure
WO2008063581A2 (en) * 2006-11-20 2008-05-29 Lutonix, Inc. Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US8430055B2 (en) 2008-08-29 2013-04-30 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
US8414909B2 (en) * 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
WO2008066899A2 (en) 2006-11-28 2008-06-05 Marinus Pharmaceuticals Nanoparticulate formulations and methods for the making and use thereof
EP2099429A2 (en) 2006-12-01 2009-09-16 Anterios, Inc. Micellar nanoparticles comprising botulinum toxin
WO2008088037A1 (ja) * 2007-01-18 2008-07-24 National University Corporation Chiba University 微粒子製剤
EP2121000B1 (en) * 2007-02-09 2015-09-23 Blanchette Rockefeller Neurosciences, Institute Therapeutic effects of bryostatins, bryologs, and other related substances on head trauma-induced memory impairment and brain injury
JP2010517759A (ja) * 2007-02-09 2010-05-27 アストラゼネカ・アクチエボラーグ 水性媒体中における固体非晶質サブミクロン粒子の安定な分散体を製造する方法
CN101244053B (zh) * 2007-02-16 2010-12-08 石药集团中奇制药技术(石家庄)有限公司 以多西他赛为主组分的新的分散体系
US20080227805A1 (en) * 2007-02-28 2008-09-18 Abbott Laboratories Sustained release parenteral formulations of buprenorphine
WO2008137717A1 (en) 2007-05-04 2008-11-13 Transave, Inc. Compositions of multicationic drugs for reducing interactions with polyanionic biomolecules and methods and uses thereof
US9333214B2 (en) 2007-05-07 2016-05-10 Insmed Incorporated Method for treating pulmonary disorders with liposomal amikacin formulations
US9119783B2 (en) 2007-05-07 2015-09-01 Insmed Incorporated Method of treating pulmonary disorders with liposomal amikacin formulations
US9114081B2 (en) 2007-05-07 2015-08-25 Insmed Incorporated Methods of treating pulmonary disorders with liposomal amikacin formulations
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
NZ581589A (en) * 2007-06-22 2012-10-26 Scidose Llc Solubilized sterile injectable formulation of docetaxel without Tween 80
US7960336B2 (en) 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
US8563527B2 (en) 2007-08-20 2013-10-22 Pharmain Corporation Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
JP5411141B2 (ja) 2007-09-10 2014-02-12 カルシメディカ,インク. 細胞内カルシウムを調節する化合物
AU2008310956B2 (en) 2007-10-08 2014-08-07 Aurinia Pharmaceuticals Inc. Ophthalmic compositions comprising calcineurin inhibitors or mTOR inhibitors
US20090130198A1 (en) 2007-11-21 2009-05-21 Innopharmax Inc. Pharmaceutical composition with enhanced bioavailability
WO2009087678A2 (en) * 2007-12-24 2009-07-16 Sun Pharma Advanced Research Company Limited Nanodispersion
US20090176892A1 (en) * 2008-01-09 2009-07-09 Pharmain Corporation Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
CN101519404B (zh) 2008-02-29 2016-01-20 唐莉 15环噻酮衍生物及其制备方法与应用
CN102036661B (zh) 2008-03-20 2016-12-28 维尔恩公司 维生素衍生物及其用途
ES2396946T3 (es) 2008-03-20 2013-03-01 Virun, Inc. Emulsiones que comprenden un derivado de PEG de tocoferol
DE102008015366A1 (de) * 2008-03-20 2009-09-24 Merck Patent Gmbh Lyophilisierte Nanoemulsion
CN101998828A (zh) * 2008-03-28 2011-03-30 粒子科学有限公司 用于使治疗剂增溶的药物溶液和方法
US8409601B2 (en) * 2008-03-31 2013-04-02 Cordis Corporation Rapamycin coated expandable devices
US8420110B2 (en) * 2008-03-31 2013-04-16 Cordis Corporation Drug coated expandable devices
US8603531B2 (en) 2008-06-02 2013-12-10 Cedars-Sinai Medical Center Nanometer-sized prodrugs of NSAIDs
WO2009158678A1 (en) 2008-06-27 2009-12-30 Children's Hospital & Research Center At Oakland Lipophilic nucleic acid delivery vehicle and methods of use therefor
WO2010009075A1 (en) * 2008-07-14 2010-01-21 The University Of North Carolina At Chapel Hill Methods and compositions comprising crystalline nanoparticles of hydrophobic compounds
FR2933871B1 (fr) * 2008-07-18 2012-12-14 Yvery Formulation destinee a ameliorer la biodisponibilite d'une molecule hydrophobe
BRPI0917719A2 (pt) 2008-08-27 2019-11-19 Calcimedica Inc compostos que modulam cálcio intracelular
AU2009293186A1 (en) * 2008-09-19 2010-03-25 Purdue Research Foundation Long-chain carboxychromanols and analogs for use as anti-inflammatory agents
US9676744B2 (en) 2008-09-19 2017-06-13 Purdue Research Foundation Long-chain carboxychromanols and analogs for use as anti-inflammatory agents
US8165658B2 (en) * 2008-09-26 2012-04-24 Medtronic, Inc. Method and apparatus for positioning a guide relative to a base
US20140105822A1 (en) * 2008-11-24 2014-04-17 Cedars-Sinai Medical Center Nanospheres comprising tocopherol, an amphiphilic spacer and a therapeutic or imaging agent
WO2010071866A2 (en) 2008-12-19 2010-06-24 Nuon Therapeutics, Inc. Combination therapy for arthritis with tranilast
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
JP5339980B2 (ja) * 2009-03-23 2013-11-13 富士フイルム株式会社 分散組成物及び分散組成物の製造方法
AU2010259184B2 (en) * 2009-06-09 2015-08-13 Aurinia Pharmaceuticals Inc. Topical drug delivery systems for ophthalmic use
WO2010146606A1 (en) 2009-06-19 2010-12-23 Sun Pharma Advanced Research Company Ltd., Nanodispersion of a drug and process for its preparation
WO2011043980A1 (en) 2009-10-07 2011-04-14 Sanford Burnham Medical Research Institute Methods and compositions related to clot-binding lipid compounds
US7741330B1 (en) 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
US7772274B1 (en) 2009-10-19 2010-08-10 Scidose, Llc Docetaxel formulations with lipoic acid
US8541465B2 (en) * 2009-10-19 2013-09-24 Scidose, Llc Docetaxel formulations with lipoic acid and/or dihydrolipoic acid
US8912228B2 (en) 2009-10-19 2014-12-16 Scidose Llc Docetaxel formulations with lipoic acid
US20110092579A1 (en) * 2009-10-19 2011-04-21 Scidose Llc Solubilized formulation of docetaxel
US8476310B2 (en) 2009-10-19 2013-07-02 Scidose Llc Docetaxel formulations with lipoic acid
CN102101863B (zh) 2009-12-17 2014-10-15 唐莉 新型环氧噻酮化合物及其制备方法和用途
US20110166214A1 (en) 2010-01-07 2011-07-07 Innopharma, Llc Methods and compositions for delivery of taxanes in stable oil-in-water emulsions
ES2999020T3 (en) 2010-02-05 2025-02-24 Phosphagenics Ltd Carrier comprising non-neutralised tocopheryl phosphate
TWI438009B (zh) * 2010-02-19 2014-05-21 Teikoku Pharma Usa Inc 紫杉烷前-乳劑調配物及其製造與使用之方法
WO2011119228A1 (en) * 2010-03-23 2011-09-29 Virun, Inc. Nanoemulsion including sucrose fatty acid ester
WO2011119863A1 (en) * 2010-03-26 2011-09-29 Onconova Therapeutics, Inc. Improved stable aqueous formulation of (e)-4-carboxystyryl-4-chlorobenzyl sulfone
RU2553350C2 (ru) 2010-03-30 2015-06-10 Фосфейдженикс Лимитед Трансдермальные пластыри
US20130030237A1 (en) 2010-04-15 2013-01-31 Charles Theuer Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitors
EP2560640A1 (en) 2010-04-19 2013-02-27 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compounds and a egfr inhibitor
CA2797533A1 (en) 2010-04-27 2011-11-10 Calcimedica, Inc. Compounds that modulate intracellular calcium
JP6112486B2 (ja) 2010-04-27 2017-04-12 カルシメディカ,インク. 細胞内カルシウムを調節する化合物
CA2798180A1 (en) 2010-05-03 2011-11-10 Teikoku Pharma Usa, Inc. Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
US20130259875A1 (en) 2010-05-11 2013-10-03 Questcor Pharmaceuticals, Inc. Acth for treatment of amyotrophic lateral sclerosis
WO2011146801A1 (en) * 2010-05-20 2011-11-24 Synta Pharmaceuticals Corp. Formulation and dosing of hsp90 inhibitory compounds
NZ604040A (en) 2010-06-03 2015-02-27 Pharmacyclics Inc The use of inhibitors of bruton’s tyrosine kinase (btk)
US8741373B2 (en) 2010-06-21 2014-06-03 Virun, Inc. Compositions containing non-polar compounds
JP5916149B2 (ja) 2010-08-27 2016-05-11 カルシメディカ,インク. 細胞内カルシウムを調節する化合物
US8796416B1 (en) 2010-10-25 2014-08-05 Questcor Pharmaceuticals, Inc ACTH prophylactic treatment of renal disorders
US8895537B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating cardiovascular diseases
US11224659B2 (en) 2010-10-29 2022-01-18 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US9744132B2 (en) 2010-10-29 2017-08-29 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US9308213B2 (en) 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US10695432B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US9504664B2 (en) 2010-10-29 2016-11-29 Infirst Healthcare Limited Compositions and methods for treating severe pain
US11730709B2 (en) 2010-10-29 2023-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US11202831B2 (en) 2010-10-29 2021-12-21 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US9271950B2 (en) 2010-10-29 2016-03-01 Infirst Healthcare Limited Compositions for treating chronic inflammation and inflammatory diseases
US9737500B2 (en) 2010-10-29 2017-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US10695431B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
WO2012063182A1 (en) * 2010-11-08 2012-05-18 Cadila Pharmaceuticals Limited Pharmaceutical composition of taxoids
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
EP2670390A2 (en) * 2011-02-04 2013-12-11 Biocopea Limited Compostions and methods for treating chronic inflammation and inflammatory diseases
WO2012122586A1 (en) 2011-03-15 2012-09-20 Phosphagenics Limited New composition
AU2012332424A1 (en) 2011-11-02 2014-06-05 Synta Pharmaceuticals Corp. Combination therapy of Hsp90 inhibitors with platinum-containing agents
US9439899B2 (en) 2011-11-02 2016-09-13 Synta Pharmaceuticals Corp. Cancer therapy using a combination of HSP90 inhibitors with topoisomerase I inhibitors
US9717678B2 (en) * 2011-11-06 2017-08-01 Murty Pharmaceuticals, Inc. Delivery systems for improving oral bioavailability of Fenobam, its hydrates, and salts
EP2780010A1 (en) 2011-11-14 2014-09-24 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with braf inhibitors
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
SG11201404640YA (en) 2012-02-10 2014-09-26 Virun Inc Beverage compositions containing non-polar compounds
US20130226550A1 (en) * 2012-02-23 2013-08-29 Hassan Benameur Systems and methods for modeling compound formulations
EP4005576B1 (en) 2012-05-21 2023-12-13 Insmed Incorporated Systems for treating pulmonary infections
AR091858A1 (es) 2012-07-25 2015-03-04 Sova Pharmaceuticals Inc INHIBIDORES DE CISTATIONIN-g-LIASA (CSE)
AR091857A1 (es) 2012-07-25 2015-03-04 Sova Pharmaceuticals Inc INHIBIDORES DE CISTATIONIN-g-LIASA (CSE)
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
US9512116B2 (en) 2012-10-12 2016-12-06 Calcimedica, Inc. Compounds that modulate intracellular calcium
MX2015006681A (es) 2012-11-29 2016-04-06 Insmed Inc Formulaciones de vancomicina estabilizadas.
CA2895357C (en) * 2012-12-21 2020-01-07 National Health Research Institutes Mesoporous silica nanoparticles for oil absorption
JP6122646B2 (ja) * 2013-01-23 2017-04-26 昭和電工株式会社 皮膚外用剤
US10232018B2 (en) 2013-03-14 2019-03-19 Mallinckrodt Ard Ip Limited ACTH for treatment of acute respiratory distress syndrome
US9351517B2 (en) 2013-03-15 2016-05-31 Virun, Inc. Formulations of water-soluble derivatives of vitamin E and compositions containing same
WO2014165672A1 (en) * 2013-04-06 2014-10-09 Igdrasol, Inc. Nanoparticle therapeutic agents, their formulations, and methods of their use
US9585417B2 (en) * 2013-06-20 2017-03-07 Vitasome Labs, Inc. Dietary supplement compositions with enhanced delivery matrix, and methods of making the same
US10299492B2 (en) * 2013-06-20 2019-05-28 James John YIANNIOS Dietary supplement compositions with enhanced delivery matrix, gummies, chocolates, atomizers and powders containing same, and methods of making same
US11044923B2 (en) 2013-06-20 2021-06-29 Vitasome Labs, Inc. Gummies containing formulations with enhanced delivery matrix, and methods of making same
US12256756B2 (en) 2013-06-20 2025-03-25 Vitasome Labs LLC. Gummies containing formulations with enhanced delivery matrix, and methods of making same
US9693574B2 (en) 2013-08-08 2017-07-04 Virun, Inc. Compositions containing water-soluble derivatives of vitamin E mixtures and modified food starch
US9896403B2 (en) * 2014-08-22 2018-02-20 Ironstone Separations, Inc. Solubilization of pterostilbene and resveratrol in aqueous beverages
WO2015054283A1 (en) 2013-10-08 2015-04-16 Calcimedica, Inc. Compounds that modulate intracellular calcium
JP6345786B2 (ja) 2013-12-05 2018-06-20 ファーマサイクリックス エルエルシー ブルトン型チロシンキナーゼの阻害剤
KR102489036B1 (ko) 2014-05-15 2023-01-13 인스메드 인코포레이티드 폐의 비-결핵성 마이코박테리아 감염을 치료하기 위한 방법
WO2016033556A1 (en) 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US9839644B2 (en) 2014-09-09 2017-12-12 ARKAY Therapeutics, LLC Formulations and methods for treatment of metabolic syndrome
US10016363B2 (en) 2014-09-18 2018-07-10 Virun, Inc. Pre-spray emulsions and powders containing non-polar compounds
US9861611B2 (en) 2014-09-18 2018-01-09 Virun, Inc. Formulations of water-soluble derivatives of vitamin E and soft gel compositions, concentrates and powders containing same
US9359316B1 (en) 2014-11-25 2016-06-07 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
MY182652A (en) * 2014-11-25 2021-01-27 Kl Kepong Oleomas Sdn Bhd Formulation for effective tocotrienol delivery
US10227333B2 (en) 2015-02-11 2019-03-12 Curtana Pharmaceuticals, Inc. Inhibition of OLIG2 activity
US20160250270A1 (en) 2015-02-27 2016-09-01 Ebbu, LLC Compositions comprising combinations of purified cannabinoids, with at least one flavonoid, terpene, or mineral
EP3261631B1 (en) 2015-02-27 2025-09-10 Curtana Pharmaceuticals, Inc. Inhibition of olig2 activity
US20180098936A1 (en) * 2015-03-23 2018-04-12 President And Fellows Of Harvard College Methods and compositions for injecting high concentration and/or high viscosity active agent solutions
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
CA2996177A1 (en) 2015-08-31 2017-03-09 Pharmacyclics Llc Btk inhibitor combinations for treating multiple myeloma
TWI838700B (zh) 2015-09-30 2024-04-11 香港商慧源香港創新有限公司 口服紫杉烷組合物及方法
US9637514B1 (en) 2015-10-26 2017-05-02 MAX BioPharma, Inc. Oxysterols and hedgehog signaling
EP3368543B1 (en) 2015-10-26 2020-09-23 MAX Biopharma, Inc. Oxysterols and hedgehog signaling
CN108601732A (zh) * 2015-12-09 2018-09-28 磷肌酸有限公司 药物制剂
WO2017119928A1 (en) * 2016-01-08 2017-07-13 Abon Pharmaceuticals, Llc Long acting injectable formulations
US10851123B2 (en) 2016-02-23 2020-12-01 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
CN109310700A (zh) 2016-04-04 2019-02-05 希诺皮亚生物科学公司 使用曲匹地尔治疗锥体外系综合征
AU2017263574B2 (en) 2016-05-12 2022-11-17 The Regents Of The University Of Michigan ASH1L inhibitors and methods of treatment therewith
WO2017205534A1 (en) 2016-05-25 2017-11-30 Concentric Analgesics, Inc. Prodrugs of phenolic trpv1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia
WO2017205762A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205769A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205766A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
SG11201901679XA (en) 2016-08-26 2019-03-28 Curtana Pharmaceuticals Inc Inhibition of olig2 activity
CA3034004C (en) 2016-08-29 2021-08-03 Canopy Growth Corporation Water soluble compositions comprising purified cannabinoids
CA3044219A1 (en) 2016-11-21 2018-05-24 Eirion Therapeutics, Inc. Transdermal delivery of large agents
EP3544614A4 (en) 2016-11-28 2020-08-05 Lipocine Inc. TESTOSTERONE UNDECANOATE ORAL TREATMENT
CN110662733A (zh) 2016-12-21 2020-01-07 埃维科生物技术有限公司 方法
WO2018129345A1 (en) 2017-01-08 2018-07-12 Resq Pharma, Inc. Methods for decreasing injuries associated with intraoperative hypotension
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
CN112739345A (zh) 2017-11-06 2021-04-30 斯奈普生物公司 Pim激酶抑制剂组合物,方法和其用途
WO2019094773A1 (en) 2017-11-10 2019-05-16 The Regents Of The University Of Michigan Ash1l inhibitors and methods of treatment therewith
CA3084809A1 (en) 2017-12-07 2019-06-13 The Regents Of The University Of Michigan Nsd family inhibitors and methods of treatment therewith
EP3508562A1 (en) * 2018-01-05 2019-07-10 Castrol Limited Micellar emulsions
US11685722B2 (en) 2018-02-28 2023-06-27 Curtana Pharmaceuticals, Inc. Inhibition of Olig2 activity
WO2019191627A1 (en) 2018-03-30 2019-10-03 Insmed Incorporated Methods for continuous manufacture of liposomal drug products
HUE063908T2 (hu) 2018-04-30 2024-02-28 Cedars Sinai Medical Center Módszerek és rendszerek gyulladásos betegségekben szenvedõ betegek kiválasztására és kezelésére
US20210121401A1 (en) * 2018-05-25 2021-04-29 Resq Pharma, Inc. Lipid emulsions and uses thereof
JP2021527064A (ja) 2018-06-07 2021-10-11 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Prc1阻害剤及びそれを用いた治療方法
WO2020010139A1 (en) 2018-07-06 2020-01-09 Cedars-Sinai Medical Center Methods of treating refractory inflammatory disease using transcriptomic and genetic risk signatures
US12150945B2 (en) 2018-07-20 2024-11-26 Lipocine Inc. Liver disease
TW202019887A (zh) 2018-07-27 2020-06-01 美商同心止痛劑股份有限公司 酚系trpv1促效劑之聚乙二醇化前藥
WO2020046466A1 (en) 2018-08-29 2020-03-05 Myos Rens Technology, Inc. Methods for alleviating, inhibiting or reversing muscle disuse atrophy in mammals
MX2021003084A (es) 2018-09-20 2021-08-11 Forge Therapeutics Inc Compuestos antibacterianos.
CA3114061A1 (en) * 2018-09-25 2020-04-02 Tolmar International, Ltd. Liquid polymer delivery system for extended administration of drugs
US12251405B2 (en) 2018-10-03 2025-03-18 Myos Corp. Spray dried follistatin product
WO2020096660A1 (en) 2018-11-06 2020-05-14 Myos Rens Technology, Inc. Methods and compositions for improving skeletal muscle protein fractional synthetic rate
WO2020135920A1 (en) * 2018-12-28 2020-07-02 Université Libre de Bruxelles Kit for inhaled chemotherapy, and treatment of lung cancer with said kit
MX2021007925A (es) 2018-12-31 2021-10-26 Biomea Fusion Llc Inhibidores irreversibles de la interaccion menina-mll.
US11833186B2 (en) 2019-02-01 2023-12-05 Myos Corp. Methods and compositions for improving quality of life and increasing activity in aging and chronically ill mammals
US12377082B2 (en) 2019-03-15 2025-08-05 Unicycive Therapeutics Inc. Nicorandil derivatives
CA3140029A1 (en) 2019-05-14 2020-11-19 Prometheus Biosciences, Inc. Tl1a patient selection methods, systems, and devices
MA56541A (fr) 2019-06-21 2022-04-27 Entelexo Biotherapeutics Inc Plateformes, compositions et méthodes d'administration de composés thérapeutiques
US11731962B2 (en) 2020-03-25 2023-08-22 Blacksmith Medicines, Inc. LpxC inhibitor and methods of making
US20210315902A1 (en) * 2020-03-25 2021-10-14 Forge Therapeutics, Inc. Lpxc inhibitor, formulations, and uses thereof
EP4161492A1 (en) * 2020-06-05 2023-04-12 University Of Cyprus Therapeutic nanocarrier system and methods of use
US11858925B2 (en) 2020-07-10 2024-01-02 The Regents Of The University Of Michigan GAS41 inhibitors and methods of use thereof
WO2022066600A1 (en) * 2020-09-22 2022-03-31 Micronization Technologies And Therapeutics Group Llc Nebulizer and nebulized anti-virals
EP4263542A1 (en) 2020-12-16 2023-10-25 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin-mll interaction
AU2022325861A1 (en) 2021-08-11 2024-02-29 Biomea Fusion, Inc. Covalent inhibitors of menin-mll interaction for diabetes mellitus
WO2023027966A1 (en) 2021-08-24 2023-03-02 Biomea Fusion, Inc. Pyrazine compounds as irreversible inhibitors of flt3
US20240409558A1 (en) 2021-09-13 2024-12-12 Biomea Fusion, Inc. Irreversible inhibitors of kras
CA3233328A1 (en) 2021-09-28 2023-04-06 Min Teng Lpxc inhibitors and uses thereof
WO2023086341A1 (en) 2021-11-09 2023-05-19 Biomea Fusion, Inc. Inhibitors of kras
WO2023119230A1 (en) 2021-12-22 2023-06-29 L'oreal Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use
PE20242008A1 (es) 2021-12-30 2024-10-03 Biomea Fusion Inc Compuestos de pirazina como inhibidores de flt3
WO2023235618A1 (en) 2022-06-03 2023-12-07 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin
AU2023363975A1 (en) 2022-10-19 2025-05-22 Myos Corp. Myogenic compounds
US20250002458A1 (en) 2023-05-24 2025-01-02 Unicycive Therapeutics Inc. Salt forms of nicorandil derivative
WO2024249950A1 (en) 2023-06-02 2024-12-05 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin
WO2025072556A1 (en) 2023-09-26 2025-04-03 Unicycive Therapeutics, Inc. Amino acid prodrugs of nicorandil

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7711916A (nl) 1977-10-29 1979-05-02 Akzo Nv Werkwijze ter bereiding van sterk geconcen- treerde farmaceutische preparaten van steroiden.
US4551332A (en) 1981-08-05 1985-11-05 Theodore Stillman Vitamin E compositions and methods
US4578391A (en) 1982-01-20 1986-03-25 Yamanouchi Pharmaceutical Co., Ltd. Oily compositions of antitumor drugs
US4439432A (en) 1982-03-22 1984-03-27 Peat Raymond F Treatment of progesterone deficiency and related conditions with a stable composition of progesterone and tocopherols
FR2581310B1 (fr) 1985-05-02 1988-09-23 Natura Medica Laboratoires Composition therapeutique comportant de l'acide a-linolenique et un compose susceptible de favoriser le passage de l'acide au travers de la membrane cellulaire et extrait de plantes comprenant l'acide et le compose
US4784845A (en) 1985-09-16 1988-11-15 American Cyanamid Company Emulsion compostions for the parenteral administration of sparingly water soluble ionizable hydrophobic drugs
US5041278A (en) 1985-10-15 1991-08-20 The Liposome Company, Inc. Alpha tocopherol-based vesicles
US4898735A (en) 1985-12-06 1990-02-06 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Liposome/doxorubicin composition and method
US4797285A (en) 1985-12-06 1989-01-10 Yissum Research And Development Company Of The Hebrew University Of Jerusalem Lipsome/anthraquinone drug composition and method
CA1338702C (en) 1987-03-05 1996-11-12 Lawrence D. Mayer High drug:lipid formulations of liposomal- antineoplastic agents
FI883337L (fi) 1987-07-16 1989-01-17 Bristol Myers Co Icke-vattenloesningar av doxorubicinhydroklorin.
US4997852A (en) * 1987-08-26 1991-03-05 Ohio State University Research Foundation Method and composition for achieving cancer chemopreventive and chemotherapeutic activity
AU620048B2 (en) 1987-09-03 1992-02-13 University Of Georgia Research Foundation, Inc., The Ocular cyclosporin composition
ATE92767T1 (de) 1987-10-19 1993-08-15 Liposome Co Inc Auf tocopherol basierte arzneimittelsysteme.
WO1991014463A1 (en) 1990-03-28 1991-10-03 Noven Pharmaceuticals, Inc. Method and device for the release of drugs to the skin
US4960814A (en) 1988-06-13 1990-10-02 Eastman Kodak Company Water-dispersible polymeric compositions
FR2641832B1 (fr) * 1989-01-13 1991-04-12 Melchior Jean Accouplement pour la transmission de couples alternes
US5532002A (en) 1989-08-17 1996-07-02 Cortecs Limited Gelatin pharmaceutical formulations
US5169846A (en) 1989-10-12 1992-12-08 Crooks Michael J Non-aqueous micellar solutions of anthelmintic benzimidazoles, closantel, or phenothiazine, and insect growth regulators
FR2657526B1 (fr) 1990-01-31 1994-10-28 Lvmh Rech Utilisation d'un phosphate d'alpha-tocopherol, ou de l'un de ses derives, pour la preparation de compositions cosmetiques, dermatologiques, ou pharmaceutiques; compositions ainsi obtenues.
NZ237084A (en) 1990-02-12 1993-10-26 Lucky Ltd Composition for the prolonged release of somatotropin comprising the somatotropin, a tocopherol component, and an assistant delaying agent
US5114957A (en) 1990-05-08 1992-05-19 Biodor U.S. Holding Tocopherol-based antiviral agents and method of using same
US5407683A (en) 1990-06-01 1995-04-18 Research Corporation Technologies, Inc. Pharmaceutical solutions and emulsions containing taxol
GB9022788D0 (en) 1990-10-19 1990-12-05 Cortecs Ltd Pharmaceutical formulations
US5179122A (en) 1991-02-11 1993-01-12 Eastman Kodak Company Nutritional supplement containing vitamin e
US6150398A (en) * 1991-05-08 2000-11-21 The United States Of America As Represented By The Department Of Health And Human Services Methods for the treatment of cancer
US5391337A (en) * 1991-06-24 1995-02-21 Ford Motor Company Method for making evaporative casting patterns
FR2678833B1 (fr) * 1991-07-08 1995-04-07 Rhone Poulenc Rorer Sa Nouvelles compositions pharmaceutiques a base de derives de la classe des taxanes.
EP0546951A1 (en) 1991-12-13 1993-06-16 The Liposome Company, Inc. Combination of liposome encapsulated antineoplastic agents, such as doxorubicin with colony stimulating factors
SE9200951D0 (sv) 1992-03-27 1992-03-27 Kabi Pharmacia Ab Pharmaceutical composition containing a defined lipid system
AU4406793A (en) 1992-06-04 1993-12-30 Clover Consolidated, Limited Water-soluble polymeric carriers for drug delivery
CA2086874E (en) * 1992-08-03 2000-01-04 Renzo Mauro Canetta Methods for administration of taxol
US5614549A (en) 1992-08-21 1997-03-25 Enzon, Inc. High molecular weight polymer-based prodrugs
US6153193A (en) 1993-04-28 2000-11-28 Supratek Pharma Inc. Compositions for targeting biological agents
GB9224502D0 (en) 1992-11-23 1993-01-13 New Roger R C Method of preparing a lipid-containing formulation
ATE169216T1 (de) * 1992-11-27 1998-08-15 Napro Biotherapeutics Inc Paclitaxel enthaltende injizierbare zusammensetzung
US6096331A (en) * 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
KR960700753A (ko) 1993-03-03 1996-02-24 후지야마 아키라 광학 이성화 억제제(optical isomerization inhibitor)
CA2092271C (en) * 1993-03-09 2009-10-13 Eddie Reed Use of g-csf for treating taxol side-effects
WO1994026254A1 (en) 1993-05-17 1994-11-24 The Liposome Company, Inc. Incorporation of taxol into liposomes and gels
US5478860A (en) 1993-06-04 1995-12-26 Inex Pharmaceuticals Corp. Stable microemulsions for hydrophobic compound delivery
DE4322826A1 (de) 1993-07-08 1995-01-12 Galenik Labor Freiburg Gmbh Pharmazeutisches Präparat
US5468769A (en) * 1993-07-15 1995-11-21 Abbott Laboratories Paclitaxel derivatives
TW406020B (en) 1993-09-29 2000-09-21 Bristol Myers Squibb Co Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent
ES2148345T3 (es) 1993-10-22 2000-10-16 Hexal Ag Composicion farmaceutica con ciclosporina a, un derivado de vitamina e y un emulsionante.
US5415869A (en) * 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
AU681231B2 (en) 1993-12-29 1997-08-21 Intarcia Therapeutics, Inc. Methods and compositions for the treatment of a host with a cellular proliferative disease
US5731334A (en) * 1994-01-11 1998-03-24 The Scripps Research Institute Method for treating cancer using taxoid onium salt prodrugs
MY112798A (en) 1994-02-04 2001-09-29 Karlshamns Lipidteknik Ab Oil-in-water emulsions
CA2183557A1 (en) 1994-03-14 1995-09-21 Mou-Ying Fu Lu Aerosol drug formulations containing vitamin e
CA2185803C (en) 1994-03-18 2006-07-11 Edward M. Rudnic Emulsified drug delivery systems
GB9409778D0 (en) 1994-05-16 1994-07-06 Dumex Ltd As Compositions
US5534499A (en) 1994-05-19 1996-07-09 The University Of British Columbia Lipophilic drug derivatives for use in liposomes
US5616330A (en) 1994-07-19 1997-04-01 Hemagen/Pfc Stable oil-in-water emulsions incorporating a taxine (taxol) and method of making same
DE4432378A1 (de) 1994-09-12 1996-03-14 Bayer Ag Injizierbare liposomale Arzneizubereitungen
ATE223205T1 (de) 1994-11-18 2002-09-15 Aphios Corp Verfahren zur herstellung von liposomen, die hydrophobische artzneistoffe enthalten
HU215966B (hu) 1994-11-21 1999-07-28 BIOGAL Gyógyszergyár Rt. Orálisan alkalmazható, ciklosporint tartalmazó, összetett emulzió-előkoncentrátum
GB9424901D0 (en) 1994-12-09 1995-02-08 Cortecs Ltd Sequestration Agents
GB9424908D0 (en) 1994-12-09 1995-02-08 Cortecs Ltd Anti-Oxidant Compositions
GB9424902D0 (en) 1994-12-09 1995-02-08 Cortecs Ltd Solubilisation Aids
CA2146098A1 (en) * 1995-01-12 1996-07-13 Ray V. Rajotte Bulk cryopreservation of biological materials and uses for cryopreserved and encapsulated biological materials
KR100239799B1 (ko) 1995-01-21 2000-02-01 손경식 경구투여용 사이클로스포린 에이 고체미셀분산체, 이의 제조 방법 및 고형제제
US5681846A (en) 1995-03-17 1997-10-28 Board Of Regents, The University Of Texas System Extended stability formulations for paclitaxel
US5616342A (en) 1995-04-11 1997-04-01 Pdt, Inc. Emulsioin suitable for administering a poorly water-soluble photosensitizing compound and use thereof
US5965160A (en) 1995-04-24 1999-10-12 Yissum Research Development Company Of The Hebrew University Of Jerusalem Self-emulsifiable formulation producing an oil-in-water emulsion
WO1996033987A1 (en) 1995-04-26 1996-10-31 Henkel Corporation Method of producing a tocopherol product
ES2164241T3 (es) * 1995-04-28 2002-02-16 Daiichi Seiyaku Co Compuestos pentaciclicos.
WO1996036316A1 (en) * 1995-05-19 1996-11-21 Abbott Laboratories Self-emulsifying formulations of lipophilic drugs
US5726181A (en) 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
GB9514878D0 (en) 1995-07-20 1995-09-20 Danbiosyst Uk Vitamin E as a solubilizer for drugs contained in lipid vehicles
US5504220A (en) 1995-08-17 1996-04-02 Eastman Chemical Company Preparation of α-tocopherol
SE9503143D0 (sv) 1995-09-12 1995-09-12 Astra Ab New preparation
KR0180334B1 (ko) 1995-09-21 1999-03-20 김윤 블럭 공중합체 미셀을 이용한 약물전달체 및 이에 약물을 봉입하는 방법
US6120794A (en) 1995-09-26 2000-09-19 University Of Pittsburgh Emulsion and micellar formulations for the delivery of biologically active substances to cells
JPH11513393A (ja) 1995-10-12 1999-11-16 ジーエス ディベロップメント エービー 皮膚又は粘膜表面へのもしくは介する活性物質の投与用医薬組成物
DE69637277T2 (de) 1995-10-17 2008-05-08 Showa Denko K.K. Hochreine tocopherolphosphate, verfahren zu ihrer herstellung und analyse, und kosmetika
US5733526A (en) * 1995-12-14 1998-03-31 Alliance Pharmaceutical Corp. Hydrocarbon oil/fluorochemical preparations and methods of use
NZ280689A (en) 1995-12-15 1997-08-22 Bernard Charles Sherma Sherman Pharmaceutical composition comprising a cyclosporipharmaceutical composition comprising a cyclosporin; a tocol, tocopherol or tocotrienol; and propylen; a tocol, tocopherol or tocotrienol; and propylene carbonate or polyethylene glycol ne carbonate or polyethylene glycol
DE19547986C1 (de) 1995-12-21 1997-07-10 Henkel Kgaa O/W-Mikroemulsionen
EP0882036A1 (de) 1996-01-29 1998-12-09 Basf Aktiengesellschaft Verfahren zur herstellung von dl-alpha-tocopherol oder dl-alpha-tocopherylacetat
AU1671197A (en) 1996-02-13 1997-09-02 Nisshin Oil Mills, Ltd., The Vaccine-containing emulsion and vaccine-containing powder for oral administration and process for producing the same
US6245349B1 (en) 1996-02-23 2001-06-12 éLAN CORPORATION PLC Drug delivery compositions suitable for intravenous injection
IL126179A (en) 1996-03-12 2003-04-10 Pg Txl Co Lp Pharmaceutical compositions containing anti-tumor drug conjugates
US5660858A (en) 1996-04-03 1997-08-26 Research Triangle Pharmaceuticals Cyclosporin emulsions
WO1997044124A1 (fr) 1996-05-23 1997-11-27 Taisho Pharmaceutical Co., Ltd. Microemulsion
EP0928136B1 (en) 1996-06-05 2003-10-22 Ashmont Holdings Limited Injectable compositions
US5877205A (en) 1996-06-28 1999-03-02 Board Of Regents, The University Of Texas System Parenteral paclitaxel in a stable non-toxic formulation
EP0910343A1 (en) 1996-07-03 1999-04-28 University Of Pittsburgh Emulsion formulations for hydrophilic active agents
US5744062A (en) 1996-08-29 1998-04-28 R.I.T.A. Corporation Balanced emulsifier blends for oil-in-water emulsions
DE19638045A1 (de) 1996-09-18 1998-03-19 Bayer Ag Injektionsformulierungen von Avermectinen und Milbemycinen
US6338943B1 (en) 1996-10-08 2002-01-15 Kreatech Biotechnology B.V. Methods for labeling nucleotides, labeled nucleotides and useful intermediates
US5827522A (en) 1996-10-30 1998-10-27 Troy Corporation Microemulsion and method
CA2189916C (en) * 1996-11-08 2001-01-16 Parkash S. Gill A new regime for paclitaxel in kaposi's sarcoma patients
US5908939A (en) 1996-11-11 1999-06-01 Roche Vitamins Inc. Method of making D,L-A-tocopherol
US6727280B2 (en) * 1997-01-07 2004-04-27 Sonus Pharmaceuticals, Inc. Method for treating colorectal carcinoma using a taxane/tocopherol formulation
US6458373B1 (en) * 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
NZ314060A (en) 1997-01-13 1997-08-22 Bernard Charles Sherman Pharmaceutical microemulsion preconcentrate comprising cyclosporin dissolved in a solvent system comprising hydrophobic solvent(s) and surfactant(s)
US6537561B1 (en) 1997-02-27 2003-03-25 Nippon Shinyaku Co., Ltd. Fat emulsion for oral administration
EP0973502A1 (en) 1997-03-12 2000-01-26 Abbott Laboratories Lipophilic binary systems for the administration of lipophilic compounds
JP4718653B2 (ja) 1997-03-12 2011-07-06 アボツト・ラボラトリーズ シクロスポリンの投与のための親水性二成分系
WO1998047486A1 (fr) 1997-04-18 1998-10-29 Taisho Pharmaceutical Co., Ltd. Microemulsion
US7030155B2 (en) * 1998-06-05 2006-04-18 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6146659A (en) * 1998-07-01 2000-11-14 Neopharm, Inc. Method of administering liposomal encapsulated taxane
WO2001025223A1 (en) * 1999-10-06 2001-04-12 The Research Foundation Of State University Of New York Stabilization of taxane-containing dispersed systems
US6136846A (en) * 1999-10-25 2000-10-24 Supergen, Inc. Formulation for paclitaxel

Also Published As

Publication number Publication date
ATE356611T1 (de) 2007-04-15
US20030147959A1 (en) 2003-08-07
CA2276730A1 (en) 1998-07-16
TW579297B (en) 2004-03-11
US6982282B2 (en) 2006-01-03
WO1998030205A1 (en) 1998-07-16
CA2276730C (en) 2004-10-26
US6667048B1 (en) 2003-12-23
TW200425913A (en) 2004-12-01
KR100612528B1 (ko) 2006-08-11
EP0981328B1 (en) 2007-03-14
US20030109575A1 (en) 2003-06-12
AR011518A1 (es) 2000-08-30
EP0981328A1 (en) 2000-03-01
DE69837328D1 (de) 2007-04-26
PT981328E (pt) 2007-05-31
ES2285753T3 (es) 2007-11-16
JP2007332157A (ja) 2007-12-27
US6458373B1 (en) 2002-10-01
KR20000069893A (ko) 2000-11-25
DK0981328T3 (da) 2007-07-02
US20030027858A1 (en) 2003-02-06
US20050142189A1 (en) 2005-06-30
US20040202712A1 (en) 2004-10-14
US20030104015A1 (en) 2003-06-05
JP2001508445A (ja) 2001-06-26
US6660286B1 (en) 2003-12-09
US20030170279A1 (en) 2003-09-11
IL130737A0 (en) 2000-06-01
DE69837328T2 (de) 2007-12-20

Similar Documents

Publication Publication Date Title
BE2018C032I2 (instruction)
IN183539B (instruction)
IN189614B (instruction)
ITMI971440A0 (instruction)
CH0944937H2 (instruction)
ITUD970058A0 (instruction)
BE2013C047I2 (instruction)
ECSDI970460S (instruction)
IN192031B (instruction)
IN184313B (instruction)
ITRM970311A0 (instruction)
BR9700653A (instruction)
ITME970005V0 (instruction)
ITGE970008V0 (instruction)
BR9701757A (instruction)
IN187641B (instruction)
ITRM970371A0 (instruction)
CN3058984S (instruction)
CN3056209S (instruction)
CN3055471S (instruction)
BY4349C1 (instruction)
CN3055179S (instruction)
BY4238C1 (instruction)
CN3055123S (instruction)
CN3054902S (instruction)